Literature DB >> 26375407

Key strategic factors for stakeholders in the current global biosimilar market.

Daniel Casey1.   

Abstract

What are the strategies of success in the global biosimilar market? In general, originators have short-term options available, such as patent litigation, but should focus on sustainable long-term strategies such as development of biobetters or incorporating biosimilars as complements to existing products. For new entrants to the market, the learning curve will be steep and only biosimilars developed to compete with the best-selling biologics will be successful over the next decade. The attitudes of physicians, patients and payers will be crucial to the reception future biosimilars will receive and it will be essential that other players contribute to this debate.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26375407     DOI: 10.1016/j.drudis.2015.09.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

Review 2.  Biosimilars: Key regulatory considerations and similarity assessment tools.

Authors:  Carol F Kirchhoff; Xiao-Zhuo Michelle Wang; Hugh D Conlon; Scott Anderson; Anne M Ryan; Arindam Bose
Journal:  Biotechnol Bioeng       Date:  2017-09-19       Impact factor: 4.530

3.  Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.

Authors:  John Waller; Emma Sullivan; James Piercy; Christopher M Black; Sumesh Kachroo
Journal:  Patient Prefer Adherence       Date:  2017-03-13       Impact factor: 2.711

4.  Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

Authors:  Emma Sullivan; James Piercy; John Waller; Christopher M Black; Sumesh Kachroo
Journal:  PLoS One       Date:  2017-04-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.